Pretzel Therapeutics is pioneering advancements in mitochondrial therapeutics, focusing on the upregulation of mitochondrial DNA (mtDNA) to address the root causes of mitochondrial diseases. These diseases arise when cells fail to produce sufficient energy, leading to severe health issues and a range of debilitating symptoms. Current treatments primarily offer supportive care and symptom management, as there are no effective curative options available. By targeting mtDNA depletion syndromes, which are characterized by critically low levels of mtDNA, Pretzel aims to develop small-molecule medicines that can enhance mtDNA levels across various organs, including the brain. This innovative approach seeks to improve survival rates, overall function, and quality of life for patients affected by these conditions.

The company recognizes the vast opportunity for therapeutic innovation in the field of mitochondrial disease, which affects approximately 1 in 5,000 individuals. With over 50 diseases linked to dysfunctional mitochondria, Pretzel's research is crucial in addressing these complex health challenges. By focusing on the underlying mechanisms of mitochondrial dysfunction rather than merely alleviating symptoms, Pretzel Therapeutics is set to transform the treatment landscape for patients and families impacted by mitochondrial diseases, potentially ushering in a new era of life-changing medicines.

United States

Pretzel Therapeutics is leading the way for a new era of life-changing medicines for patients and families affected by mitochondrial disease. The company's mission is to develop groundbreaking therapies to reverse mitochondrial dysfunction through mitochondrial biology.

Pretzel Therapeutics

Company Details